Clinical Trial Update: Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the efficacy and safety of activated recombinant human factor VII for treating bleeding after hematopoietic stem cell transplantation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Bleeding Disorders
• Surgical Bleeding

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Acquired Bleeding Disorder, Bleeding During/Following Surgery | Phase 2 | Status: TERMINATED